###begin article-title 0
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 61 66 <span type="species:ncbi:9606">Human</span>
Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: RGC SMA GC JLR CHJ. Performed the experiments: RGC CC XS GDD RL TG SJ. Analyzed the data: RGC CC XS GDD TG JLR ZLJ SJ. Contributed reagents/materials/analysis tools: ZLJ. Wrote the paper: RGC CHJ.
###end p 1
###begin p 2
###xml 256 257 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 426 427 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 431 432 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 437 438 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 165 170 <span type="species:ncbi:9606">human</span>
###xml 199 204 <span type="species:ncbi:10090">mouse</span>
###xml 247 252 <span type="species:ncbi:9606">human</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 693 698 <span type="species:ncbi:10090">mouse</span>
###xml 805 810 <span type="species:ncbi:9606">human</span>
###xml 1137 1142 <span type="species:ncbi:9606">human</span>
IL-18 has pleotropic effects on the activation of T cells during antigen presentation. We investigated the effects of human IL-18 on the engraftment and function of human T cell subsets in xenograft mouse models. IL-18 enhanced the engraftment of human CD8+ effector T cells and promoted the development of xenogeneic graft versus host disease (GVHD). In marked contrast, IL-18 had reciprocal effects on the engraftment of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in the xenografted mice. Adoptive transfer experiments indicated that IL-18 prevented the suppressive effects of Tregs on the development of xenogeneic GVHD. The IL-18 results were robust as they were observed in two different mouse strains. In addition, the effects of IL-18 were systemic as IL-18 promoted engraftment and persistence of human effector T cells and decreased Tregs in peripheral blood, peritoneal cavity, spleen and liver. In vitro experiments indicated that the expression of the IL-18Ralpha was induced on both CD4 and CD8 effector T cells and Tregs, and that the duration of expression was less sustained on Tregs. These preclinical data suggest that human IL-18 may have use as an adjuvant for immune reconstitution after cytotoxic therapies, and to augment adoptive immunotherapy, donor leukocyte infusions, and vaccine strategies.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 93 96 85 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Okamura1">[1]</xref>
###xml 98 101 90 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Ushio1">[2]</xref>
###xml 208 211 200 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Nakanishi1">[3]</xref>
###xml 213 216 205 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Gracie1">[4]</xref>
###xml 341 344 333 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Gu1">[5]</xref>
###xml 346 349 338 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Ghayur1">[6]</xref>
###xml 419 422 411 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Okamura1">[1]</xref>
###xml 440 443 432 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Stoll1">[7]</xref>
###xml 472 475 464 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Gerdes1">[8]</xref>
###xml 509 512 501 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Takeuchi1">[9]</xref>
Initially isolated from macrophages as a potent interferon-gamma (IFN-gamma)-inducing factor [1], [2], Interleukin-18 (IL-18) is a multifunctional cytokine affecting both innate and adaptive immune responses [3], [4]. IL-18 is produced as an inactive precursor (pro-IL-18), which is activated by proteolytic cleavage, primarily by caspase-1 [5], [6]. Pro-IL-18 is produced by multiple cell types, including macrophages [1], dendritic cells [7], vascular endothelial cells [8], and intestinal epithelial cells [9].
###end p 4
###begin p 5
###xml 176 179 176 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Nakanishi1">[3]</xref>
###xml 257 258 257 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 493 497 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Mathur1">[10]</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Mathur2">[11]</xref>
###xml 584 588 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Tsutsui1">[12]</xref>
###xml 671 675 667 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Son1">[13]</xref>
###xml 915 919 911 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Marshall1">[14]</xref>
###xml 943 947 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Luo1">[15]</xref>
###xml 1012 1016 1008 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Tatsumi1">[16]</xref>
###xml 1018 1022 1014 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Tanaka1">[17]</xref>
###xml 1060 1064 1056 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Xu1">[18]</xref>
###xml 1146 1150 1142 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-VidalVanaclocha1">[19]</xref>
###xml 1307 1311 1303 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Cho1">[20]</xref>
###xml 1402 1406 1398 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Zhang1">[21]</xref>
Numerous effector functions have been attributed to IL-18. Perhaps the best characterized of these is IL-18's context-dependent induction of Th1 or Th2 CD4 T cell polarization [3]. In the presence of IL-12, IL-18 drives the Th1 polarization of activated CD4+ T cells. However, in the absence of IL-12 (or in the presence of IL-2 or IL-4), IL-18 promotes IgE expression and Th2 differentiation. More recently, IL-18 has been demonstrated, in synergy with IL-23, to drive TH17 cell polarization [10], [11]. IL-18 also exerts multiple effects on NK cells, including increased cytoxicity [12], and in synergy with IL-2, promotion of NK cell expansion and IFNgamma production [13]. Given its widespread immune-augmenting functions, it is not surprising that IL-18 has been evaluated in numerous animal models of cancer. For example, IL-18 enhances the efficacy of DNA vaccines directed against prostate-specific antigen [14] or Fos-related antigen [15]. Additionally, IL-18 augments the efficacy of DC-based vaccines [16], [17] as well as whole-cell tumor vaccines [18]. However, IL-18 has also been reported to enhance tumor progression (reviewed in [19]). For example, tumor-produced IL-18 induces Fas ligand expression in melanoma cells, possibly resulting in escape from NK cell-mediated immune surveillance [20]. Furthermore, IL-18 has been shown to increase the invasiveness of myeloid leukemia lines [21].
###end p 5
###begin p 6
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Boraschi1">[22]</xref>
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Gracie2">[23]</xref>
###xml 297 301 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Pittoni1">[24]</xref>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Robertson1">[25]</xref>
###xml 475 479 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Leonard1">[26]</xref>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 393 399 <span type="species:ncbi:9606">humans</span>
IL-18 has also been implicated in multiple autoimmune-associated pathologies (reviewed in [22]). For example, high levels of IL-18 are found in the synovial fluid of rheumatoid arthritis patients [23], and alleviation of rheumatoid arthritis symptoms is associated with a decrease in IL-18 levels [24]. Paradoxically, given its' proinflammatory properties, IL-18 is well tolerated and safe in humans [25]. In contrast, IL-12 is toxic at doses three orders of magnitude lower [26].
###end p 6
###begin p 7
###xml 280 281 280 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 367 368 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 372 373 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 378 379 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 512 519 512 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 584 585 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 282 287 <span type="species:ncbi:9606">human</span>
###xml 358 363 <span type="species:ncbi:9606">human</span>
The rationale for the present study was to determine if IL-18 might present a less toxic alternative to IL-12 as an adjunct for cancer adoptive transfer immunotherapy. In the study described herein, we demonstrate that IL-18 administration resulted in increased engraftment of CD8+ human T cells. Concurrently, IL-18 administration resulted in a decrease in human CD4+CD25+FoxP3+ regulatory T cells (Tregs). Furthermore, we find that IL-18 augmented xenogeneic GVHD, and overrode the suppressive effect of Tregs in vivo. Our findings indicate that by simultaneously affecting both CD8+ T cells and Tregs, IL-18 may alter the set point of an immune response, underscoring the potential utility of IL-18 as an adjuvant in cancer therapy.
###end p 7
###begin title 8
Methods
###end title 8
###begin title 9
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 9
###begin p 10
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 143 147 140 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 143 147 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>null</sup></italic>
###xml 153 157 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 164 168 158 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 163 168 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m<sup>null</sup></italic>
###xml 170 174 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Christianson1">[27]</xref>
###xml 183 187 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 198 202 188 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 198 202 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>null</sup></italic>
###xml 209 213 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Shultz1">[28]</xref>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
All animal experiments were approved by the University of Pennsylvania Institutional Animal Care and Use Committee. NOD/scid/beta2microglobulinnull (NOD/scid/beta2mnull) [27] and NOD/scid/IL-2rgammanull (NOG) [28] mice were purchased from the Jackson Laboratory. Animals were bred in the Animal Services Unit of the University of Pennsylvania. The mice were housed under specific pathogen-free conditions in microisolator cages and given unrestricted access to autoclaved food and acidified water. Animals of both sexes were used for experiments at 6-9 weeks of age.
###end p 10
###begin title 11
Cells and Animal Injections
###end title 11
###begin p 12
###xml 136 141 <span type="species:ncbi:9606">Human</span>
Peripheral blood mononuclear cells (PBMCs) were obtained by leukapheresis of healthy volunteer donors by the University of Pennsylvania Human Immunology Core. All specimens were collected under a University Institutional Review Board-approved protocol, and informed consent was obtained from each donor. Cells were injected intraperitoneally into non-irradiated host animals as described in the individual experiments.
###end p 12
###begin p 13
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Kirkpatrick1">[29]</xref>
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 50 55 <span type="species:ncbi:9606">human</span>
Recombinant human IL-18 (SB-485232) and pegylated human IL-18 (GSK-189720) were prepared as previously described at GlaxoSmithKline [29]. Subcutaneous injections of 15 microg/animal were performed daily for the recombinant product and twice weekly for the pegylated product, taking into consideration the increased persistence of the pegylated IL-18.
###end p 13
###begin title 14
Animal Necropsy
###end title 14
###begin p 15
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Animals were sacrificed by CO2 asphyxiation. Peripheral blood was obtained by cardiac puncture, and the spleen, liver, lung, and gut were isolated and portions were fixed in 4% paraformaldehyde. Liver leukocytes were separated by Ficoll density gradient centrifugation and splenocytes were prepared by mechanical disassociation. Cells were retrieved from the peritoneal cavity by PBS lavage.
###end p 15
###begin title 16
Immunohistochemistry
###end title 16
###begin p 17
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 245 251 <span type="species:ncbi:10090">murine</span>
###xml 277 282 <span type="species:ncbi:9606">human</span>
###xml 423 427 <span type="species:ncbi:9925">goat</span>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
Mouse tissues were fixed in 4% paraformaldehyde and embedded in paraffin. 5-6 microm sections were cut for immunohistochemical staining. Following deparaffinization and high temperature antigen unmasking procedures, sections were incubated with murine monoclonal antibodies to human CD25 (Clone 4C9 [Vector], 1:100), or Foxp3 (Clone236A/E7 [AbCam], 1:40). Sections were then incubated with biotinylated secondary antibody (goat anti-mouse IgG [Vector]) and signal was localized using 3,3'-diaminobenzidine tetrahydrochloride (DAB, [Vector]) as the chromogen. Hematoxylin was used for counterstaining. Positively stained cells were quantified with Metamorph software (Universal Imaging Corporation) using the Manual Count option. Quantification was performed in a blinded manner. For each organ, at least 8 fields per animal were tabulated.
###end p 17
###begin title 18
Flow cytometry
###end title 18
###begin p 19
###xml 565 566 565 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 179 184 <span type="species:ncbi:9606">human</span>
###xml 494 499 <span type="species:ncbi:9606">Human</span>
###xml 555 560 <span type="species:ncbi:9606">human</span>
###xml 604 609 <span type="species:ncbi:9606">human</span>
###xml 697 702 <span type="species:ncbi:9606">human</span>
After euthanasia, peripheral blood, peritoneal cavity washings, spleen, and liver were obtained from euthanized animals. Single cell suspensions were stained with conjugated anti-human lymphocyte surface markers (CD45, clones H130 or 2D1, CD4, clone SK3, CD8, clone SK1 or 3B5, and CD25, clone M-A251, all from BD Pharmingen) and Foxp3 (Clone 206D, Biolegend). Cell populations were analyzed using either LSRII or FACSCalibur flow cytometers (Becton Dickinson) and Flowjo software (Tree Star). Human lymphocytes were initially identified by gating on the human CD45+ population within the live gate, and human lymphocyte subsets were further defined within this population. The absolute number of human cells was determined using TruCount tubes (BD Biosciences) or a Multisizer 3 (Beckman Coulter).
###end p 19
###begin title 20
Adoptive Transfer of Ex Vivo Expanded Tregs
###end title 20
###begin p 21
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 14 18 14 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Basu1">[30]</xref>
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Suhoski1">[31]</xref>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 272 276 272 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 391 395 391 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Basu1">[30]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CD4+CD25high cells were isolated from PBMCs using magnetic beads (Miltenyi Biotech) as described [30]. Gamma-irradiated (100 Gy) K562-based antigen presenting cells modified to express CD64, CD86 and OX40L [31] were used to stimulate purified populations of CD4+CD25high cells, which were expanded ex vivo in the presence of 300 U/ml IL-2 (Chiron) and 100 ng/ml Rapamycin (Calbiochem) [30]. After one growth cycle (approximately 14-21 days), the cells were harvested and used for injection as described in the text.
###end p 21
###begin title 22
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vitro</italic>
In Vitro Suppression Assay
###end title 22
###begin p 23
###xml 312 313 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 428 429 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1075 1076 1067 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1081 1082 1073 1074 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1089 1093 1081 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Basu1">[30]</xref>
###xml 137 142 <span type="species:ncbi:9606">human</span>
###xml 762 767 <span type="species:ncbi:9606">human</span>
Following harvest of expanded T cells (Tregs and control CD4 cells), varying numbers of Tregs were plated in 100 microl of X-VIVO 15+10% human AB serum in round bottom 96 well plates (Corning Incorporated, Corning, NY). Frozen autologous PBMCs were thawed, CFSE-labeled, and resuspended in culture medium at 1x107/ml. Anti-CD3 beads (Invitrogen) were added at a ratio of 1 bead per cell. 100 microl of PBMC cell suspension (1x106 cells) was added to individual wells in a 96 well plate. CFSE-labeled PBMCs without CD3 beads (and lacking Tregs) were used as negative controls; CFSE-labeled PBMC stimulated with anti-CD3 beads (no Tregs) were used as positive controls. Where indicated, the suppression assay was performed in the presence of 500 ng/ml recombinant human IL-18. The cultures were harvested four days later and stained with APC-conjugated anti-CD8 (BD Pharmingen). Data were acquired on a FACSCalibur flow cytometer using Cell Quest Pro software and analyzed using FlowJo software. Quantitative analysis of Treg suppression capacity was performed by gating on CD8+ CFSE+ cells [30].
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
All results were expressed as means+/-standard deviation. Unless otherwise indicated, the statistical significance of differences between groups was evaluated by two-sample t tests assuming equal variance or the Mann-Whitney rank sum test. Survival data were analyzed by lifetable methods using log rank analysis performed using SysStat (Systat Software, Inc.).
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 363 367 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Robertson1">[25]</xref>
###xml 369 373 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Herzyk1">[32]</xref>
###xml 465 469 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Christianson1">[27]</xref>
###xml 471 475 463 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Shultz1">[28]</xref>
###xml 569 573 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 580 584 569 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 579 584 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m<sup>null</sup></italic>
###xml 696 700 685 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 706 710 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Christianson1">[27]</xref>
###xml 721 725 710 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 732 736 718 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 731 736 717 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m<sup>null</sup></italic>
###xml 1027 1034 1013 1020 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1A</bold>
###xml 1027 1034 1013 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g001"><bold>Fig. 1A</bold></xref>
###xml 1143 1144 1129 1130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1174 1175 1160 1161 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1212 1226 1198 1212 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1B and 1C</bold>
###xml 1212 1226 1198 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g001"><bold>Fig. 1B and 1C</bold></xref>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 356 362 <span type="species:ncbi:9606">humans</span>
###xml 411 416 <span type="species:ncbi:9606">human</span>
###xml 452 457 <span type="species:ncbi:10090">mouse</span>
###xml 548 553 <span type="species:ncbi:9606">human</span>
###xml 585 589 <span type="species:ncbi:10090">mice</span>
###xml 597 601 <span type="species:ncbi:10090">mice</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
###xml 737 741 <span type="species:ncbi:10090">mice</span>
###xml 785 790 <span type="species:ncbi:9606">human</span>
###xml 953 958 <span type="species:ncbi:9606">human</span>
###xml 1021 1025 <span type="species:ncbi:10090">mice</span>
In preliminary experiments we evaluated recombinant human IL-18 at doses from 1 to 100 microg/mouse/day for anti-tumor effects in xenografted mice (data not shown), and 15 microg was chosen as a daily dose based on tolerability and efficacy, and because this dose is less than the equivalent maximum tolerated dose that has been established in monkeys and humans [25], [32]. The effects of IL-18 were tested on human T cell subsets using two humanized mouse models [27], [28]. Initially, we determined if IL-18 directly affected the engraftment of human T cells in NOD/scid/beta2mnull mice. These mice, in addition to lacking mature B and T cells, have reduced levels of NK cells compared to NOD/scid mice [27]. When NOD/scid/beta2mnull mice were injected intraperitoneally with PBMC, human CD45 positive cells were recovered from peripheral blood, liver and spleen. Daily subcutaneous injections of IL-18 caused a substantial increase in the number of human leukocytes recovered from the blood, liver and spleens of the mice (Fig. 1A). However, the leukocyte promoting effect of IL-18 was entirely attributable to increased engraftment of CD8+ T cells, as the number of CD4+ T cells was not increased by IL-18 (Fig. 1B and 1C). No NK cells or B cells were observed at this time point (data not shown).
###end p 27
###begin title 28
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid/</italic>
###xml 85 86 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
###xml 86 90 83 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 43 48 <span type="species:ncbi:9606">Human</span>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 110 115 <span type="species:ncbi:9606">human</span>
Human IL-18 Promotes Systemic Increases in Human CD8 T Cell Numbers in NOD/scid/beta2mnull mice injected with human PBMCs.
###end title 28
###begin p 29
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 15 19 12 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 14 19 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m<sup>null</sup></italic>
###xml 66 67 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 629 630 620 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 651 652 642 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 677 678 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 178 183 <span type="species:ncbi:9606">human</span>
###xml 355 360 <span type="species:ncbi:9606">Human</span>
###xml 619 624 <span type="species:ncbi:9606">human</span>
###xml 642 647 <span type="species:ncbi:9606">human</span>
###xml 668 673 <span type="species:ncbi:9606">human</span>
###xml 975 979 <span type="species:ncbi:10090">mice</span>
NOD/scid/beta2mnull mice were injected intraperitoneally with 5x107 human PBMCs and 24 hours later, a three week course of daily subcutaneous injections of 15 microg recombinant human IL-18 was initiated. At the end of the injection time course, the animals were sacrificed, peripheral blood was collected, and liver and spleen homogenates were prepared. Human cell populations were detected by flow cytometry. Absolute cell numbers in the peripheral blood were determined using Tru-Count tubes; absolute cell numbers from spleen and liver were determined using a Coulter Multisizer 3. The mean+/-s.d. is shown for (A) human CD45+ cells, (B) human CD4+ cells, and (C) human CD8+ cells. Open bars represent values from mock-treated animals; filled bars represent values from IL-18 treated animals. These data are a representative single experiment of seven different experiments. Asterisks indicate significant differences between mock- and IL-18-treated animals (n = 6 to 10 mice/group; p<0.05).
###end p 29
###begin p 30
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 508 512 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Trenado1">[33]</xref>
###xml 514 518 514 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Mutis1">[34]</xref>
###xml 584 591 584 591 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1B</bold>
###xml 584 591 584 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g001"><bold>Fig. 1B</bold></xref>
###xml 716 722 716 722 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2</bold>
###xml 716 722 716 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g002"><bold>Fig. 2</bold></xref>
###xml 766 767 766 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 771 772 771 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 879 893 879 893 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2A and 2B</bold>
###xml 879 893 879 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g002"><bold>Fig. 2A and 2B</bold></xref>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 205 210 <span type="species:ncbi:9606">human</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
As is shown below, we observed that the IL-18 treated mice developed xenogeneic GVHD more rapidly than mice engrafted with PBMC only. We first considered the hypothesis that the IL-18-mediated increase in human CD8+ cells could account for this. However, an alternative hypothesis was also considered, that decreased engraftment with regulatory T cells could also account for this, because others have shown that regulatory T cell numbers and function can influence the onset and severity of xenogeneic GVHD [33], [34]. Although IL-18 did not influence the total number of CD4 cells (Fig. 1B), there were significant decreases in regulatory T cells in the IL-18 treated mice, as judged by CD25 and FoxP3 expression (Fig. 2). The percentage and absolute number of CD4+CD25+ cells was decreased in all organs and tissues examined, i.e. blood, spleen, liver, and peritoneal cavity (Fig. 2A and 2B).
###end p 30
###begin title 31
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid/</italic>
###xml 59 63 56 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 58 63 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m<sup>null</sup></italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 83 88 <span type="species:ncbi:9606">Human</span>
Human IL-18 Mediates a Decrease in Tregs in NOD/scid/beta2mnull mice Injected with Human PBMCs.
###end title 31
###begin p 32
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 50 54 47 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 50 54 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>null</sup></italic>
###xml 619 620 608 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 624 625 613 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 262 267 <span type="species:ncbi:9606">human</span>
###xml 378 383 <span type="species:ncbi:9606">human</span>
###xml 536 541 <span type="species:ncbi:9606">human</span>
###xml 906 911 <span type="species:ncbi:9606">human</span>
5x107 PBMCs were transferred into NOD/scid /beta2Mnull mice. The day following cell injection, a three week course of subcutaneous huIL-18 injections was initiated. Animals in the experiment depicted in panel A received twice-weekly doses of 15 microg pegylated human IL-18, while the animals in the experiments depicted in panel B received daily doses of 15 microg recombinant human IL-18. (A) At the end of IL-18 treatment, cells isolated from the peripheral blood, peritoneal cavity, spleen and liver were stained with antibodies to human CD45, CD4, and CD25 and analyzed by flow cytometry. The mean percentage of CD+CD25+ cells from each tissue is depicted. Filled bars represent values obtained from IL-18-treated animals; open bars represent values obtained from mock-treated animals. (B) Paraffin sections from the spleens of mock- or IL-18-treated animals were reacted with antibodies specific for human CD25 or Foxp3 . Antibody-reactive cells per 400X field were enumerated blindly, and the mean+/-s.d. depicted. Solid bars depict sections from IL-18-treated animals, while open bars represent sections from mock-treated animals. The experiment in panel A was performed 2 times, and the experiment in panel B was performed 6 times. Asterisks indicate significant differences between mock- and IL-18-treated animals (n = 8/group; p<0.05).
###end p 32
###begin p 33
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 186 190 183 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 185 190 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m<sup>null</sup></italic>
###xml 255 259 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 270 274 263 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 270 274 263 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>null</sup></italic>
###xml 365 369 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Shultz1">[28]</xref>
###xml 478 479 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 583 584 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 592 599 585 592 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3A</bold>
###xml 592 599 585 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g003"><bold>Fig. 3A</bold></xref>
###xml 625 629 618 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 636 640 626 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 636 640 626 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>null</sup></italic>
###xml 696 697 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 701 702 691 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 707 708 697 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 729 736 719 726 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3B</bold>
###xml 729 736 719 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g003"><bold>Fig. 3B</bold></xref>
###xml 815 816 805 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 820 821 810 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 826 827 816 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1046 1053 1036 1043 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3C</bold>
###xml 1046 1053 1036 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g003"><bold>Fig. 3C</bold></xref>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 323 328 <span type="species:ncbi:9606">human</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 468 473 <span type="species:ncbi:9606">human</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
It was possible that the distinct effects of IL-18 on human lymphocyte subsets were due to relative efficiencies of engraftment for effector and regulatory subsets in the NOD/scid/beta2mnull mice. To test this possibility, PBMCs were transferred into NOD/scid/IL-2rgammanull (NOG) mice. This strain is highly permissive to human hematopoietic stem cell engraftment [28]. In NOG mice injected with PMBC, the mice treated with IL-18 had consistently elevated numbers of human CD45+ cells in the peripheral blood, and this increase was entirely accounted for by increased numbers of CD8+ cells (Fig. 3A) as was the case for NOD/scid/beta2Mnull mice. The NOG mice also had reciprocal decreases in CD4+CD25+Foxp3+ cells in the blood (Fig. 3B) and all tissues examined (data not shown). The IL-18 mediated decrease in CD4+CD25+FoxP3+ cells was not due to decreased recovery of the cells, as tissue sections examined by immunohistochemistry also documented consistent decreases in cells that stained for Foxp3 (data not shown). Furthermore, as shown in Fig. 3C, the CD8:Treg ratios in the peripheral blood of individual animals were markedly increased by IL-18 treatment.
###end p 33
###begin title 34
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid/</italic>
###xml 79 83 76 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 78 83 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m<sup>null</sup></italic>
###xml 4 9 <span type="species:ncbi:9606">Human</span>
###xml 84 88 <span type="species:ncbi:10090">Mice</span>
The Human IL-18-Mediated Decrease in Tregs is Not Restricted to NOD/scid/beta2mnull Mice.
###end title 34
###begin p 35
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 19 23 15 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 19 23 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>null</sup></italic>
###xml 58 59 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 231 232 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 250 251 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 255 256 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 261 262 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 416 417 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 419 420 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 425 426 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 30 34 <span type="species:ncbi:10090">mice</span>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 222 227 <span type="species:ncbi:9606">human</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
NOD/scid/IL-2rgammanull (NOG) mice were injected with 5x106 human PBMCs, and 24 hours later, a three week course of daily subcutaneous injections of 15 microg recombinant human IL-18 was initiated. The absolute numbers of human CD8+ cells (A) and CD4+CD25+Foxp3+ cells (B) in the peripheral blood were determined using TruCount tubes. Values from individual mice are depicted. (C) The ratio of CD8 cell number to CD4+25+Foxp3+ cell number for each animal in panels A and B is plotted on a log scale. In panels A and B, asterisks (*) indicate significant differences between mock- and IL-18-treated animals (n = 6 to 8/group; p<0.05). In panel C, asterisks (**) indicate p<0.001.
###end p 35
###begin p 36
###xml 169 175 169 175 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 4</bold>
###xml 169 175 169 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g004"><bold>Fig. 4</bold></xref>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 276 277 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 469 470 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 474 475 474 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 483 484 483 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 488 489 488 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
To assess the effects of IL-18 treatment on human T cell differentiation in NOG mice after IL-18 treatment, peripheral blood and spleen were examined by flow cytometry (Fig. 4). There were only minor effects of IL-18 on the fraction of T cells with a central memory (CD27+CD28+) phenotype, and the modest effects were different in blood and spleen. There was only a slight effect of IL-18 on the appearance of T cells with a senescent or effector memory phenotype (CD28+CD57+ or CD27+CD57+).
###end p 36
###begin title 37
###xml 11 16 <span type="species:ncbi:9606">Human</span>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Effects of Human IL-18 on CD8 T Cell Differentiation in NOG mice.
###end title 37
###begin p 38
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 264 265 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 133 138 <span type="species:ncbi:9606">human</span>
###xml 341 346 <span type="species:ncbi:9606">human</span>
###xml 356 361 <span type="species:ncbi:9606">human</span>
NOG mice were injected intraperitoneally with 5x106 human PBMCs, and beginning 1 day later, were injected with 15 microg recombinant human IL-18 daily for three weeks. Spleen tissue and peripheral blood were collected and analyzed for the presence of different CD8+ T cell subsets by flow cytometry. Cell populations were initially gated on human CD45 and human CD8. Filled bars represent values mean+/-s.d. obtained from IL-18-treated animals; open bars represent values obtained from mock-treated animals. The data in this figure represent results from one of two independent experiments. Asterisks indicate significant differences between mock- and IL-18-treated animals (p<0.05).
###end p 38
###begin p 39
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 65 69 62 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 65 69 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>null</sup></italic>
###xml 192 198 189 195 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 5</bold>
###xml 192 198 189 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g005"><bold>Fig. 5</bold></xref>
###xml 645 665 642 662 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplemental Fig. S1</bold>
###xml 645 665 642 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003289.s001"><bold>Supplemental Fig. S1</bold></xref>
###xml 665 670 662 667 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and </bold>
###xml 670 672 667 669 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S2</bold>
###xml 670 672 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003289.s002"><bold>S2</bold></xref>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
As was mentioned above, we observed that both the NOD/scid/beta2Mnull and NOG mouse strains had earlier onset and more severe xenogeneic GVHD after PBMC engraftment and human IL-18 treatment (Fig. 5). Clinical appearance and examination of weight curves revealed that IL-18 treated mice had more significant manifestations of GVHD as indicated by lethargy, hunched posture, generalized erythema, and a progressive reduction in mean weights from pretransplant levels (data not shown). Pathologic examination revealed that the IL-18 treated mice had more severe tissue infiltration and inflammation of the lung, liver and gastrointestinal tracts (Supplemental Fig. S1 and S2).
###end p 39
###begin title 40
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Human IL-18 Accelerates Xenogeneic GVHD in NOG mice.
###end title 40
###begin p 41
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
5x106 PBMC were transferred into NOG mice on day 0, and IL-18 or PBS injected daily starting on day 1. On the x-axis are days after transfer of cells. On the y-axis is the proportion of recipients surviving (n = 8/group; P<.02).
###end p 41
###begin p 42
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Hoffmann1">[35]</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Taylor1">[38]</xref>
###xml 233 234 233 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 236 240 236 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 274 278 274 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 293 294 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 296 300 296 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Godfrey1">[37]</xref>
###xml 524 525 524 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 529 530 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 565 572 565 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 588 589 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 613 620 613 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 693 694 693 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 698 699 698 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 734 741 734 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 754 755 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 757 758 757 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 766 779 766 779 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 6A and B</bold>
###xml 766 779 766 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g006"><bold>Fig. 6A and B</bold></xref>
###xml 829 836 829 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 922 923 922 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 972 973 972 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1035 1044 1035 1044 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 6C&#8211;E</bold>
###xml 1035 1044 1035 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g006"><bold>Fig. 6C&#8211;E</bold></xref>
###xml 1079 1080 1079 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1155 1156 1155 1156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1267 1268 1267 1268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1285 1289 1285 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Mutis1">[34]</xref>
###xml 1305 1312 1305 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1363 1364 1363 1364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1464 1465 1464 1465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1517 1518 1517 1518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1639 1646 1639 1646 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 6E</bold>
###xml 1639 1646 1639 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g006"><bold>Fig. 6E</bold></xref>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 651 655 <span type="species:ncbi:10090">mice</span>
###xml 800 804 <span type="species:ncbi:10090">mice</span>
###xml 880 884 <span type="species:ncbi:10090">mice</span>
###xml 1047 1051 <span type="species:ncbi:10090">Mice</span>
###xml 1199 1204 <span type="species:ncbi:9606">human</span>
###xml 1280 1284 <span type="species:ncbi:10090">mice</span>
###xml 1380 1384 <span type="species:ncbi:10090">mice</span>
###xml 1477 1481 <span type="species:ncbi:10090">mice</span>
To address the mechanisms for these observations, we used an adoptive transfer model of effector and regulatory T cells that we and others have developed [35]-[38]. PBMCs were subjected to immunoaffinity bead separation to obtain CD4+25high cells and PBMC depleted of CD4+25high cells. The CD4+25high cells at baseline were >70% Foxp3+, and these cells were expanded using K562 cells expressing CD64, CD86, and OX40L in the presence of IL-2 and rapamycin as described [37]. NOG mice were injected with PBMC plus enriched CD4+CD25- effector cells, or with PBMC plus ex vivo-expanded CD4+25+ Tregs. IL-18 treatment in vivo accelerated GVHD lethality in mice engrafted with PBMC plus enriched CD4+CD25- effector cells, or with PBMC plus ex vivo expanded CD4+25+ cells (Fig. 6A and B). In contrast, most mice engrafted with PBMC and ex vivo expanded Tregs had long term survival. The mice were monitored for engraftment of CD8+ T cells by periodic measurements of absolute CD8+ T cell numbers in peripheral blood using the Trucount assay (Fig. 6C-E). Mice engrafted with PBMC and CD4+ effector cells had a progressive increase in the number of circulating CD8+ T cells. Previous studies have shown that human Tregs prevent the expansion of the presumably xenoreactive CD8+ T cells in mice [34]. We found that ex vivo expanded Tregs also prevented the expansion of CD8+ T cells in the mice. However, IL-18 treatment resulted in a striking increase in the numbers of CD8+ T cells in mice engrafted with either PBMCs and CD4+ effectors or with PBMCs and Tregs. In fact, all IL-18-treated animals were sacrificed early due to acute GVHD symptoms (Fig. 6E and data not shown). Thus, in the presence of IL-18, Tregs failed to control CD8+ T cell proliferation. However, the Kaplan-Meier curves show a significant difference between each of the 4 groups, indicating that Tregs have an effect even in the face of IL18 treatment.
###end p 42
###begin title 43
###xml 10 15 <span type="species:ncbi:9606">Human</span>
###xml 70 74 <span type="species:ncbi:10090">Mice</span>
Effect of Human IL-18 on Treg-Induced Delay of Xenogeneic GVHD in NOG Mice.
###end title 43
###begin p 44
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 109 110 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 190 191 190 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 764 765 760 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 285 290 <span type="species:ncbi:9606">human</span>
###xml 314 319 <span type="species:ncbi:9606">Human</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 755 760 <span type="species:ncbi:9606">human</span>
NOG mice were injected with 2x107 Treg-depleted human PBMCs supplemented with either 4 million autologous CD4+CD25- T cells ("CD4 T cells") or 4 million autologous, ex vivo-expanded CD4+CD25+ cells ("Tregs"). One cohort of each group received daily injections of 15 microg recombinant human IL-18 for three weeks. Human cell engraftment in the peripheral blood was measured 11, 22, and 30 days post-injection. The animals were followed until the onset of xenogeneic GVHD. (A) Experimental overview. (B) Kaplan-Meier Survival Analysis (Log-Rank) of the indicated cohorts of mice. The Holm-Sidak method for multiple comparisons (significance level 0.05) was performed, and showed significant differences between all groups. (C-E) Peripheral blood levels of human CD8+ T cells were measured at Day 11 (C), Day 22 (D), and Day 30 (E) post-injection. Note that all IL-18-treated animals are not represented in panel E due to their death from acute GVHD.
###end p 44
###begin p 45
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 223 231 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 340 348 340 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 497 504 497 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 521 527 521 527 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 7</bold>
###xml 521 527 521 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g007"><bold>Fig. 7</bold></xref>
###xml 641 642 637 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 644 645 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 652 653 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 655 656 651 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 910 916 902 908 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 8</bold>
###xml 910 916 902 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g008"><bold>Fig. 8</bold></xref>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
Because IL-18 was able to override some of the effects of the Tregs as indicated by the findings of increased CD8+ T cells in mice given adoptively transferred Tregs, we next evaluated the effects of IL-18 on Treg function in vitro. We found that the addition of IL-18 to culture medium did not affect the population doubling rate of Tregs in vitro after anti-CD3/CD28 stimulation, in the presence or absence of IL-2 (data not shown). Furthermore, IL-18 did not affect the suppressive function of ex vivo expanded Tregs (Fig. 7) or the expression of Foxp3 (data not shown). Finally, the upregulation of IL-18Ralpha did not differ between CD4+25- or CD4+25+ T cells in culture after activation using a variety of stimulation conditions. However, it is notable that the expression of IL-18Ralpha was not sustained on the regulatory T cells after day 3 in culture, in contrast to bulk CD4 and CD8 T cell subsets (Fig. 8).
###end p 45
###begin title 46
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human IL-18 Does Not Prevent Treg Suppressive Function in Vitro.
###end title 46
###begin p 47
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 324 329 <span type="species:ncbi:9606">human</span>
Purified Tregs were expanded ex vivo for 18 days, and then tested in an in vitro suppression assay. Autologous PBMCs were labeled with CFSE and stimulated using anti-CD3 Ab coated beads and mixed with either no Tregs (top panel) or expanded Tregs at the indicated ratio (Treg:PBMC) in the presence or absence of recombinant human IL-18 (500 ng/ml). Histograms show the expansion of CD8+ cells on day 4 of culture.
###end p 47
###begin title 48
Rapid Down Regulation of IL18-Ralpha on Tregs Following Cell Activation.
###end title 48
###begin p 49
###xml 157 162 <span type="species:ncbi:9606">human</span>
Purified populations of Tregs, as well as bulk CD4 and CD8 cells, were activated with either alphaCD3/alphaCD28 beads, PHA (5 microg/ml), or PHA+recombinant human IL-18 (500 ng/ml). IL-18Ralpha expression was measured by flow cytometry. IL-18Ralpha MFI on effector CD4 cells (A), Tregs (B) and effector CD8 cells (C) is plotted before stimulation and 1, 2, and 3 days following stimulation.
###end p 49
###begin title 50
Discussion
###end title 50
###begin p 51
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 599 603 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Dinarello1">[39]</xref>
###xml 605 609 605 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Logan1">[40]</xref>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 82 87 <span type="species:ncbi:9606">human</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 503 508 <span type="species:ncbi:10090">mouse</span>
This study demonstrates that in immune-deficient mice engrafted with human PBMCs, human IL-18 administration exerts opposite effects upon two human cell populations: CD8+ T cell numbers are increased, while CD4+CD25+FoxP3+ Treg cell numbers are markedly decreased. The altered ratio of effector to Treg engraftment was functionally important as judged by the accelerated onset and severity of xenogeneic GVHD in the recipient mice. These effects were unexpected because we are not aware of studies with mouse IL-18 that have revealed differential effects of IL-18 on regulatory and effector T cells [39], [40].
###end p 51
###begin p 52
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Son1">[13]</xref>
###xml 336 344 336 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 545 552 541 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 711 715 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-June1">[41]</xref>
###xml 791 795 787 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Zeiser1">[42]</xref>
###xml 868 872 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Reddy1">[43]</xref>
###xml 1023 1027 1015 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Iwai1">[44]</xref>
###xml 1205 1209 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Agaugue1">[45]</xref>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 687 692 <span type="species:ncbi:9606">human</span>
###xml 697 702 <span type="species:ncbi:10090">mouse</span>
###xml 724 729 <span type="species:ncbi:10090">mouse</span>
###xml 863 867 <span type="species:ncbi:10090">mice</span>
###xml 896 901 <span type="species:ncbi:10090">mouse</span>
###xml 1049 1054 <span type="species:ncbi:9606">human</span>
###xml 1349 1353 <span type="species:ncbi:10090">mice</span>
Our studies revealed several potential mechanisms for the effects of IL-18. IL-18 can cause the expansion of mouse NK cells [13], but has not been reported to directly mediate the expansion of T cells. Consistent with this, we were unable to demonstrate a direct effect of IL-18 on the expansion of human effector or regulatory T cells in vitro. However, we found that the expression of the IL-18Ralpha subunit was more prolonged on effector T cells than Tregs, providing a potential mechanism to explain the reciprocal effects that we observed in vivo on the effects of IL-18 on effector T cells and Tregs. There may be important species specific differences in the biology of IL-18 on human and mouse T cells [41]. In the mouse, IL-18 has a protective effect on CD4(+)-mediated acute GVHD [42], and blockade of IL-18 accelerates acute GVHD-related mortality in mice [43]. Recent studies in the mouse indicate that IL18 has a role in promoting an IFN-gamma dependent positive regulation of memory CD8 T cell proliferation [44]. Recent studies with human cells indicate that the interaction of IL-18 treated NK cells and DCs induces maturation of DCs that subsequently promote Th1 and IFN-gamma secretion [45]. Together, the above studies are consistent with our findings, and suggest a mechanism that IL-18 promotes engraftment of CD8 cells in the mice at the expense of regulatory T cells, leading to increased memory CD8 cells and increased xenogeneic GVHD.
###end p 52
###begin p 53
###xml 293 301 293 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g004">Figure 4</xref>
###xml 505 513 505 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003289-g006">Figure 6</xref>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
A complete mechanistic understanding of the effects mediated by IL-18 is not yet available from the present findings. It is still not clear which T cell subsets are preferentially expanded during IL-18 therapy in the mice, although we found some selective effects on subsets of CD8 T cells in Figure 4. We do not yet know if CD8 T cells need to be activated in order to be regulated by IL-18. Similarly, we do not yet know if CD4 T cells need to be present for the IL-18 effects on CD8 cells. Our data in Figure 6 suggest that the effects on CD8 T cells and Tregs are independent.
###end p 53
###begin p 54
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Dinarello2">[46]</xref>
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Calvani1">[47]</xref>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Gracie2">[23]</xref>
###xml 341 345 341 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Dai1">[48]</xref>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Takada1">[54]</xref>
###xml 470 474 470 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Viglietta1">[55]</xref>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 104 107 <span type="species:ncbi:9606">man</span>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 173 179 <span type="species:ncbi:9606">humans</span>
IL-18 has been proposed to have a role in a number of inflammatory and autoimmune disorders in mice and man [46]. In mice, IL-18 may have a role in lupus nephritis [47]. In humans, IL-18 over-expression has been reported in rheumatoid arthritis, sarcoidosis, adult-onset Still's disease, vasculitis, lupus, urticaria and histiocytosis [23], [48]-[54]. Tregs have been reported to be decreased or to have decreased functional activity in a number of autoimmune disorders [55], and it is possible that an imbalance of Tregs and effector T cells due to differential IL-18 signaling contributes to the loss of tolerance.
###end p 54
###begin p 55
###xml 80 84 80 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Sutmuller1">[56]</xref>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Zhang2">[57]</xref>
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Sato1">[58]</xref>
###xml 289 290 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 425 429 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Hodi1">[59]</xref>
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Quezada1">[60]</xref>
###xml 501 502 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-June2">[61]</xref>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
###xml 361 367 <span type="species:ncbi:9606">humans</span>
Depletion of Tregs in tumor bearing mice enhances the response to immunotherapy [56]. A high ratio of effector CD8 T cells to Tregs in the tumor microenvironment has been shown to be a favorable prognostic feature in patients with ovarian cancer [57], [58]. An increase in the ratio of CD8+ T effector to regulatory cells in syngeneic mouse tumor models and in humans with cancer correlates with responses to immunotherapies [59], [60]. Thus, the ability of IL-18 to increase the ratio of effector CD8+ T cells to Tregs may have important implications for therapeutic vaccines and adoptive transfer strategies [61].
###end p 55
###begin p 56
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Sutmuller1">[56]</xref>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Zhang2">[57]</xref>
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Sato1">[58]</xref>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 592 596 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Hodi1">[59]</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Quezada1">[60]</xref>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
###xml 502 507 <span type="species:ncbi:10090">mouse</span>
###xml 528 534 <span type="species:ncbi:9606">humans</span>
The ability of IL-18 to increase the ratio of effector CD8+ T cells to Tregs may have important implications for therapeutic vaccines and cancer therapy. Depletion of Tregs in tumor bearing mice enhances the response to immunotherapy [56]. A high ratio of effector CD8 T cells to Tregs in the tumor microenvironment has been shown to be a favorable prognostic feature in patients with ovarian cancer [57], [58]. Furthermore, an increase in the ratio of CD8+ T effector to regulatory cells in syngeneic mouse tumor models and in humans with cancer correlates with responses to immunotherapies [59], [60].
###end p 56
###begin p 57
###xml 173 177 173 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Woo1">[62]</xref>
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Gajewski1">[63]</xref>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Zou1">[64]</xref>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003289-Curiel1">[65]</xref>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 520 525 <span type="species:ncbi:9606">human</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
Our findings may have important implications for cancer therapy due to the immunosuppressive tumor microenvironment. Cancer patients have increased tumor infiltrating Tregs [62], and in many cases, CD8+ CTLs from the tumor environment are dysfunctional [63], [64]. Recently, it has become more widely appreciated that successful immunotherapy requires neutralization of the immunosuppressive features of the tumor microenvironment, in particular Tregs [65]. Thus, by inhibiting Tregs and promoting conventional T cells, human IL-18 may have potential to restore immunocompetence in cancer patients, and thereby augment the effects of cytotoxic and biologic therapies, in order to provoke and maintain an effective anti-tumor immune response. Finally, IL-18 may have potential to augment the anti-tumor effects of donor leukocyte infusions by promoting effector T cells at the expense of regulatory T cell expansion.
###end p 57
###begin title 58
Supporting Information
###end title 58
###begin p 59
###xml 155 159 <span type="species:ncbi:10090">mice</span>
Photomicrographs of lung and liver tissue sections taken from animals after xenogeneic GVHD induction. 10 million PBMC were transferred into NOG recipient mice followed by daily injections of IL-18 (15 microg) or PBS. Animals were euthanized on day 20 when recipients of PBMC and IL-18 were moribund. Sections were stained with hematoxylin and eosin. Left: Lung sections taken from PBMC or PBMC+IL-18 recipients, demonstrating severe inflammation and lymphocytic infiltration in IL-18 recipients. Right: Liver sections demonstrating marked periportal lymphocytic infiltrates in IL-18 recipients.
###end p 59
###begin p 60
(5.49 MB TIF)
###end p 60
###begin p 61
Click here for additional data file.
###end p 61
###begin p 62
###xml 158 165 158 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003289.s001">Fig. S1</xref>
Photomicrographs of gut tissue sections taken from animals after xenogeneic GVHD induction. Sections were obtained from the animals described above in Suppl. Fig. S1. Left: low magnification. Middle: higher magnification. Right: highest magnification.
###end p 62
###begin p 63
(5.14 MB TIF)
###end p 63
###begin p 64
Click here for additional data file.
###end p 64
###begin p 65
We thank Ella Ofori, Laura Pell and Michelle Kanther for expert technical assistance.
###end p 65
###begin title 66
References
###end title 66
###begin article-title 67
Cloning of a new cytokine that induces IFN-gamma production by T cells.
###end article-title 67
###begin article-title 68
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 71 87 <span type="species:ncbi:562">Escherichia coli</span>
Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein.
###end article-title 68
###begin article-title 69
Interleukin-18 regulates both Th1 and Th2 responses.
###end article-title 69
###begin article-title 70
Interleukin-18.
###end article-title 70
###begin article-title 71
Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.
###end article-title 71
###begin article-title 72
Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production.
###end article-title 72
###begin article-title 73
###xml 56 62 <span type="species:ncbi:10090">murine</span>
###xml 67 72 <span type="species:ncbi:9606">human</span>
Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development.
###end article-title 73
###begin article-title 74
###xml 67 72 <span type="species:ncbi:9606">human</span>
Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis.
###end article-title 74
###begin article-title 75
###xml 120 125 <span type="species:ncbi:10090">mouse</span>
Immunohistochemical and immuno-electron-microscopic detection of interferon-gamma-inducing factor ("interleukin-18") in mouse intestinal epithelial cells.
###end article-title 75
###begin article-title 76
T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype.
###end article-title 76
###begin article-title 77
Stat3 and Stat4 direct development of IL-17-secreting Th cells.
###end article-title 77
###begin article-title 78
###xml 81 87 <span type="species:ncbi:10090">murine</span>
IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.
###end article-title 78
###begin article-title 79
Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells.
###end article-title 79
###begin article-title 80
Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine.
###end article-title 80
###begin article-title 81
A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
###end article-title 81
###begin article-title 82
Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy.
###end article-title 82
###begin article-title 83
Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.
###end article-title 83
###begin article-title 84
###xml 68 74 <span type="species:ncbi:10090">murine</span>
###xml 110 116 <span type="species:ncbi:10090">murine</span>
Synergistic antileukemia effect of combinational gene therapy using murine beta-defensin 2 and IL-18 in L1210 murine leukemia model.
###end article-title 84
###begin article-title 85
Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression.
###end article-title 85
###begin article-title 86
###xml 53 59 <span type="species:ncbi:10090">murine</span>
Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates.
###end article-title 86
###begin article-title 87
IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression.
###end article-title 87
###begin article-title 88
IL-18 in autoimmunity: review.
###end article-title 88
###begin article-title 89
A proinflammatory role for IL-18 in rheumatoid arthritis.
###end article-title 89
###begin article-title 90
Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13.
###end article-title 90
###begin article-title 91
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
###end article-title 91
###begin article-title 92
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
###end article-title 92
###begin article-title 93
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice.
###end article-title 93
###begin article-title 94
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.
###end article-title 94
###begin article-title 95
###xml 70 75 <span type="species:ncbi:9606">human</span>
A bicistronic expression system for bacterial production of authentic human interleukin-18.
###end article-title 95
###begin article-title 96
###xml 41 46 <span type="species:ncbi:9606">Human</span>
Foxp3 Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin.
###end article-title 96
###begin article-title 97
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
###end article-title 97
###begin article-title 98
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
Immunopharmacology of recombinant human interleukin-18 in non-human primates.
###end article-title 98
###begin article-title 99
Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells.
###end article-title 99
###begin article-title 100
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.
###end article-title 100
###begin article-title 101
###xml 45 50 <span type="species:ncbi:9606">human</span>
Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.
###end article-title 101
###begin article-title 102
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.
###end article-title 102
###begin article-title 103
###xml 18 23 <span type="species:ncbi:9606">human</span>
In vitro expanded human CD4+CD25+ T regulatory cells markedly inhibit allogeneic dendritic cell stimulated MLR cultures.
###end article-title 103
###begin article-title 104
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.
###end article-title 104
###begin article-title 105
IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family.
###end article-title 105
###begin article-title 106
Interleukins 18 and 21: biology, mechanisms of action, toxicity, and clinical activity.
###end article-title 106
###begin article-title 107
Clinical application of expanded CD4+25+ cells.
###end article-title 107
###begin article-title 108
Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease.
###end article-title 108
###begin article-title 109
Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis.
###end article-title 109
###begin article-title 110
An IFN-gamma-IL-18 Signaling Loop Accelerates Memory CD8+ T Cell Proliferation.
###end article-title 110
###begin article-title 111
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human natural killer cells exposed to IL-2, IL-12, IL-18 or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells.
###end article-title 111
###begin article-title 112
Interleukin-18 and the pathogenesis of inflammatory diseases.
###end article-title 112
###begin article-title 113
Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18.
###end article-title 113
###begin article-title 114
Cellular targets of interleukin-18 in rheumatoid arthritis.
###end article-title 114
###begin article-title 115
Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis.
###end article-title 115
###begin article-title 116
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Serum interleukin-18 in patients with chronic ordinary urticaria: association with disease activity.
###end article-title 116
###begin article-title 117
Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
###end article-title 117
###begin article-title 118
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Serum concentration of interleukin-18 is up-regulated in patients with ANCA-associated vasculitis.
###end article-title 118
###begin article-title 119
###xml 98 106 <span type="species:ncbi:9606">patients</span>
A/C polymorphism in the interleukin-18 coding region among Taiwanese systemic lupus erythematosus patients.
###end article-title 119
###begin article-title 120
Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity.
###end article-title 120
###begin article-title 121
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Loss of functional suppression by CD4(+)CD25(+) regulatory T cells in patients with multiple sclerosis.
###end article-title 121
###begin article-title 122
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
###end article-title 122
###begin article-title 123
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
###end article-title 123
###begin article-title 124
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
###end article-title 124
###begin article-title 125
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
###end article-title 125
###begin article-title 126
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
###end article-title 126
###begin article-title 127
Principles of adoptive T cell cancer therapy.
###end article-title 127
###begin article-title 128
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non small cell lung cancer and late-stage ovarian cancer.
###end article-title 128
###begin article-title 129
Immune resistance orchestrated by the tumor microenvironment.
###end article-title 129
###begin article-title 130
Immunosuppressive networks in the tumour environment and their therapeutic relevance.
###end article-title 130
###begin article-title 131
Tregs and rethinking cancer immunotherapy.
###end article-title 131
###begin p 132
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Z.L.J. is an employee of GlaxoSmithKline; the other authors have no competing financial interests to declare.
###end p 132
###begin p 133
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by research funding from GlaxoSmithKline to CHJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 133

